What We Do:
The Science Policy Branch provides scientific leadership and advice on a wide range of drug abuse research and policy issues:
- Synthesizes and disseminates information about NIDA-supported science and programmatic activities
- Identifies, analyzes, and prepares briefing materials on behalf of the Institute
- Provides timely responses to inquiries from Congress, other public agencies, professional organizations, and the public
- Develops and provides scientific review of NIDA publications and multimedia initiatives
- Monitors and coordinates NIDA’s response to broad policy issues related to drug use and addiction
- Coordinates NIDA’s strategic planning, performance reporting, program evaluation, and OMB clearance for NIDA-sponsored data collections
Emily Jones, Ph.D., Branch Chief
Emily Jones joined the Science Policy Branch in January 2017. Previously, she was a policymaker and health services researcher at the HHS Office of the Assistant Secretary of Planning and Evaluation (ASPE). Before that, she was Team Lead for HITECH Act evaluation at the HHS Office of the National Coordinator (ONC) for Health IT, and part of the team implementing the Affordable Care Act in federally-qualified health centers (FQHCs) at the Health Resources and Services Administration (HRSA). Emily also served as the Assistant Director of the Outstanding Scholar Program in the Bureau of Competition at the Federal Trade Commission; she has over 10 years of federal experience. She gained research experience at the Urban Institute, the Georgetown Health Policy Institute, and the George Washington University Department of Health Policy, where she served as Associate Director of the Geiger Gibson/RCHN Foundation Research Collaborative. She holds a Doctorate in Health Policy from George Washington University, a Masters in Public Policy from Georgetown, and a Bachelor's in Organizational Behavior and Management from Brown University.
Emily Einstein, Ph.D., Deputy Branch Chief
Dr. Einstein joined the Science Policy Branch, Office of Science Policy and Communications as Health Science Policy Analyst in January 2015. On the SPB team, Dr. Einstein develops materials to communicate the science of drugs of abuse and substance use disorders to members of the public, the scientific community, and the government, with an emphasis on prescription opioids and heroin. Prior to joining OSPC, Dr. Einstein was an American Association for the Advancement of Science (AAAS) Science and Technology Policy Fellow in the Office of Autism Research Coordination at NIMH. Dr. Einstein received her Ph.D. in neuroscience from Yale University, where her research was focused on the molecular and cellular mechanisms of opioid reward.
Ruben Baler, Ph.D., Health Scientist Administrator
Dr. Ruben Baler joined the Science Policy Branch in NIDA’s Office of Science Policy and Communications in October 2004 as a Health Science Administrator. His early publications focused on gene promoter architecture and gene expression in the brain’s clock. At NIDA, he writes and lectures about the neurobiology of drug abuse and addiction for a range of audiences. Dr. Baler has gathered critical insight from diverse disciplines, which he combines to advance NIDA’s scientific mission as it intersects with cellular and molecular biology, genetics, immunology, bioinformatics, neuroscience, and neuroethics. Dr. Baler’s many contributions to other dissemination efforts include scientific writing (English and Spanish), teaching, public speaking to lay audiences, and fielding interview requests for a variety of print, radio, and broadcast media outlets. Prior to coming to NIDA, Dr. Baler worked at the National Institute of Mental Health, where he conducted basic research on the molecular basis of circadian gene expression in vertebrates. He received his Ph.D. in Microbiology and Molecular Biology from the University of Miami in 1993 and completed his postdoctoral training at the National Institute of Child Health and Human Development, specializing in Molecular Chronobiology.
David Bochner, Ph.D., Health Science Policy Analyst
David Bochner joined the Science Policy Branch in June 2018. Prior to joining the SPB, Dr. Bochner worked in the Office of Science Policy in the NIH Office of the Director, where he focused on analyzing, evaluating, and communicating evidence to NIH staff, Congress, and the public about a variety of issues, including NIH’s priority-setting process and the impact of the NIH-funded research portfolio on health and the economy. Prior to that, he was an American Association for the Advancement of Science (AAAS) Science and Technology Policy Fellow in the same office. He holds a doctorate in Neuroscience from Stanford University, where his research was focused on mechanisms of neural plasticity, and a BA in Biology from Harvard University, with a focus on neurobiology.
Jessica Cotto, M.P.H., Health Science Policy Analyst
Ms. Cotto joined the Science Policy Branch in 2009 and serves as a Health Science Policy Analyst. Her primary responsibilities include analyzing data and synthesizing information from disparate sources to identify trends related to substance use and contributing to a variety of science-based materials to inform the public about drug use, abuse and addiction. She earned her Bachelor’s Degree in Cellular and Molecular Biology from San Diego State University and a Master’s of Public Health in Epidemiology and Biostatistics from George Washington University. Prior to NIDA, Ms. Cotto served as a Clinical Research Associate for The Children's National Medical Center, the National Institute of Allergy and Infectious Diseases, and the National Cancer Institute.
Genevieve deAlmeida-Morris, Ph.D., Health Research Evaluator
Dr. deAlmeida-Morris joined the Science Policy Branch in the Office of Science Policy and Communications in 2004 as a Health Science Administrator (Health Research Evaluator). Her primary responsibilities include evaluation, Office of Management and Budget clearance, and Government Performance and Results Act (GPRA) coordination. Prior to coming to NIDA, Dr. deAlmeida-Morris worked at the National Institute of Nursing Research as Acting Chief of the Office of Science Policy and Communications and as Program Analyst for Evaluation; at the Veterans Health Administration as Health Science Specialist; and at the Fogarty International Center writing evaluation proposals. She conducts successful program evaluations of NIDA’s research and dissemination programs and of trans-NIH programs for which NIDA has the lead. She serves on trans-NIH Workgroups and Evaluation Committees for GPRA, research training, and for the evaluation of trans-NIH programs such as the NIH Common Fund.
Eric Wargo Ph.D., Science Writer
Dr. Wargo currently serves as a Science Writer in the Science Policy Branch (SPB) of NIDA’s Office of Science Policy and Communications. Before coming to NIH in 2012, he was Editorial Director at the Association for Psychological Science in Washington, DC. There he managed two top-ranked journals: Current Directions in Psychological Science and Psychological Science in the Public Interest. In SPB, Dr. Wargo writes and edits a variety of materials for a range of audiences, including fact sheets, blog posts, and other web materials; treatment guides for clinicians; and responses to congressional inquiries and other special projects. He received a Ph.D. in Anthropology from Emory University in 2000.